|
Study
|
Outcome
|
Sample size (n)
|
Evaluation time of markers and outcome (months)
|
Contrast of markers' concentrations (Recovered patients as
reference group)
|
|
|
Chronic
|
Recovered
|
|
Higher
|
Lower
|
Non difference
|
|
| Chow, 2011 [29] |
Joint pain |
4 |
26 |
3 |
IL-6, GM-CSF |
Eotaxin, HGF |
|
| Restrepo, 2022 [22] |
Musculoskeletal disorder |
28 |
55 |
3 |
|
IL-10, MIP-1 |
IFN-γ, TNF-α, IL-6, IL-12, IL-8, MCP-1, RANTES |
| Sepúlveda-Delgado, 2017 [37] |
Joint pain |
6 |
4 |
3 and 12 |
IL-6, RF |
|
CRP |
| Chaaithanya, 2011 [36] |
Joint pain |
10 |
6 |
10 |
IL-1β, IL-1Ra, MCP-1, IL-6, IL-8, G-CSF, MIP-1α, MIP-1β |
IL-5, RANTES |
IL-2R, IL-10, IP-10, MIG |
| Schilte, 2013 [38] |
Joint pain |
20 |
22 |
36 |
IL-1α |
|
GM-CSF, IFN-γ, IL-1β, IL-10, IL-12, IL-15, IL-17, IL-18, IL-1RA, IL-2,
IL-23, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, MCP-1, MIP-1 α, MIP-1β,
RANTES, TNF-α, TNF- β, IP-10 |
| Ninla-Aesong, 2019 [35] |
Joint pain |
63 |
30 |
60 |
MMP-1, MMP-3 |
TNF-α |
IL-4, IL-10, IL-12, IL-6, IL-1β, IL-8, IL-17A, RANTES, IFN-γ, TGF- β,
MCP-1 |
